ALPACCA

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Dec 4, 2025 → Oct 7, 2026

Cited window

Dec 4, 2025 → Oct 7, 2026

Retrieved

Nov 1, 2026

Title

A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)

Registry

NCT07185997

Study IDs

FURMO-006

Sponsor

ArriVent BioPharma, Inc.

Design

Phase 3 · Interventional, randomized, parallel

Status

Recruiting

Enrollment

480 estimated

Registered

2025-09-22

Start

2025-12-17 actual

Primary completion

2029-02 estimated

Primary endpoint

Progression Free Survival (PFS) determined by blinded independent central review (BICR)

Interventions

2 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –6 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits apply, so some matching discussion may be missing.
• –Discussion centered on ALPACCA and its registry names may miss relevant views expressed without those names or with other wording.
• –Some passages were not fully assessed for clinician views, so the report is not a complete account of the clinical decision or public discussion.
• –Repeated posts and reposts do not establish independent agreement or the prevalence of a view.
• –Le is described in the source as involved in ALPACCA; this is source-described involvement, not an independently confirmed trial role.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –The earlier efficacy studies are not named in the relevant posts. Their populations, assessment details and comparability cannot be reconstructed from these statements.
• –No full protocol or results publication for the exact trial was available in the sources reviewed. Regulatory labels matching the intervention names as searched were not identified; that absence does not establish lack of approval.
• –The sources provide no ALPACCA efficacy or safety outcome, no comparative CNS estimate and no answer to the global-approval question.

How reports are built and checked: Methods.

Last checked for new commentary Nov 1, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "ALPACCA" (NCT07185997), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "alpacca-07185997". If you cannot make requests, read https://www.erudio.com/reports/alpacca-nct07185997.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT07185997", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct07185997 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/alpacca-nct07185997.json
curl https://www.erudio.com/reports/alpacca-nct07185997.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "alpacca-07185997" })